Is the Recommended Dose of Efavirenz Optimal in Young West African Human Immunodeficiency Virus-Infected Children?
暂无分享,去创建一个
S. Urien | P. Van de Perre | P. Msellati | S. Diagbouga | F. Rouet | J. Treluyer | D. Hirt | H. Hien | H. Peyrière | B. Nacro | E. Zouré | Mathieu Olivier
[1] M. Kurowski,et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. , 2008, The Journal of antimicrobial chemotherapy.
[2] L. Mofenson,et al. Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV‐infected Children Participating in an Area‐under‐the‐curve Controlled Trial , 2008, Clinical pharmacology and therapeutics.
[3] M. Peeters,et al. Impact of HIV-1 Genetic Diversity on Plasma HIV-1 RNA Quantification: Usefulness of the Agence Nationale de Recherches sur le SIDA Second-Generation Long Terminal Repeat-Based Real-Time Reverse Transcriptase Polymerase Chain Reaction Test , 2007, Journal of acquired immune deficiency syndromes.
[4] G. Maartens,et al. High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children , 2007, Journal of acquired immune deficiency syndromes.
[5] W. Kreuz,et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. , 2006, European journal of medical research.
[6] F. van Leth,et al. Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study , 2005, Antiviral therapy.
[7] Catia Marzolini,et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.
[8] Ingrid A. Beck,et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. , 2004, The Journal of infectious diseases.
[9] C. Fletcher,et al. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. , 2003, Seminars in pediatric infectious diseases.
[10] David A. Flockhart,et al. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[11] E. Delaporte,et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal , 2003, AIDS.
[12] J. Ena,et al. Once-a-day highly active antiretroviral therapy: a systematic review. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] D. Hillaire‐buys,et al. Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma. , 2003, Journal of chromatographic science.
[14] Jacques Fellay,et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.
[15] F. Maggiolo,et al. Once-A-Day Therapy for HIV Infection: A Controlled, Randomized Study in Antiretroviral-Naive HIV-1-Infected Patients , 2002, Antiviral therapy.
[16] Stuart L. Beal,et al. Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[17] E. Lagarde,et al. Condom use and its association with HIV/sexually transmitted diseases in four urban communities of sub-Saharan Africa , 2001, AIDS.
[18] A. Telenti,et al. Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .
[19] M. Gersten,et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. , 1999, The New England journal of medicine.
[20] N H Holford,et al. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. , 1999, Computer methods and programs in biomedicine.
[21] Ross Ihaka,et al. Gentleman R: R: A language for data analysis and graphics , 1996 .